First Trust Heitman Global Prime Real Estate ETF (PRME) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is PRME's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.32 per share a year ago.…

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 -- -- Receiv…

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…

PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.…

Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of …

-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most…

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application f…

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced…

BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional inves…
No recent releases where the company itself is speaking.
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

